"目录号: HY-14136
GPCR/G Protein-
Rimonabant(SR141716)是中心CB1受体反向激动剂，Ki为1.8 nM。
Cannabinoid Receptor
相关产品
WIN 55,212-2 Mesylate-AM251-Rimonabant Hydrochloride-Taranabant-AM630-Org 27569-Otenabant-Pregnenolone-A-836339-CB1-IN-1-JWH-133-Bay 59-3074-BML-190-JD-5037-(±)-SLV319-
生物活性
Description
Rimonabant(SR141716) is a selective central cannabinoid (CB1) receptor inverse agonist with Ki of 1.8 nM.IC50 Value: 1.8 nM(Ki)Target: CB1 Receptorin vitro: Rimonabant dose-dependently reduces ACAT activity in Raw264.7macrophages with IC50 of 2.9 μM and isolated peritoneal macrophages. Rimonabant inhibits ACATactivity in intact CHO-ACAT1 and CHO-ACAT2 cells and in cell-free assays with approximately equal efficiency with IC50 of 1.5 μM and 2.2 μM for CHO-ACAT1 and CHO-ACAT2, respectively. Consistent with ACAT inhibition, Rimonabant treatment blocks ACAT dependent processes in macrophages, oxysterol-induced apoptosis and acetylated-LDL induced foam cell formation. Rimonabant antagonizes the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and adenylyl cyclase activity in rat brain membranes in a concentration-dependent manner.in vivo: Rimonabant (10 mg/kg by gavage) is fed for 2 weeks to 3-month-old male obese Zucker rats as an impaired glucose tolerance model and for 10 weeks to 6-month-old male obese Zucker rats as a model of the metabolic syndrome. RANTES (Regulated upon Activation, Normal T cell Expressed, and Secreted) and MCP-1 (monocyte chemotactic protein-1) serum levels are increased in obese vs lean Zucker rats and significantly reduced by long-term treatment with Rimonabant, which slowes weight gain in rats with the metabolic syndrome. Neutrophils and monocytes are significantly increased in young and old obese vs lean Zucker rats and lowered by Rimonabant. Platelet-bound fibrinogen is significantly enhanced in obese vs lean Zucker rats of both age, and is reduced by Rimonabant. Platelets from obese rats are more sensitive to thrombin-induced aggregation and adhesion to fibrinogen, which are both attenuated by Rimonabant therapy.
Clinical Trial
NCT00263042
Sanofi
Cardiovascular Disease
December 2005
Phase 3
NCT00228176
Sanofi
Carotid Artery Plaque-Arteriosclerosis-Obesity-Metabolic Syndrome X
August 2005
Phase 3
NCT00576667
Sanofi
Fatty Liver
January 2008
Phase 3
NCT00577148
Sanofi
Fatty Liver
February 2008
Phase 3
NCT00584389
University of Surrey-European Foundation for the Study of Diabetes-Royal Surrey County Hospital
Obesity
July 2007
Phase 4
NCT00325650
Sanofi
Prediabetic State
May 2006
Phase 3
NCT00299325
Sanofi
Metabolic Syndrome
February 2006
Phase 3
NCT00547118
University of Maryland-National Institute on Drug Abuse (NIDA)
Schizophrenia-Schizoaffective Disorder-Obesity-Hypertension-Smoking
November 2007
Phase 2
NCT00690456
Sanofi
Diabetes Mellitus, Type 2
May 2008
Phase 3
NCT00603109
Weill Medical College of Cornell University-National Institutes of Health (NIH)-PWSAUSA
Prader-willi Syndrome
August 2007
Phase 3
NCT00478972
Sanofi
Obesity-Diabetes Mellitus Type 2
April 2007
Phase 3
NCT00754689
Sanofi
Diabetes Mellitus, Type 2
September 2008
Phase 3
NCT00478595
Sanofi
Obesity-Diabetes Mellitus Type 2
April 2007
Phase 3
NCT00449605
Sanofi
Diabetes Mellitus, Type 2
March 2007
Phase 3
NCT00464256
Sanofi
Smoking Cessation
April 2004
Phase 3
NCT00464165
Sanofi
Smoking Cessation
November 2002
Phase 3
NCT00546325
Sanofi
Diabetes Mellitus, Type 2
October 2007
Phase 3
NCT00358228
Sanofi
Smoking Cessation
September 2002
Phase 3
NCT00405808
Sanofi
Obesity
December 2006
Phase 3
NCT00458081
Sanofi
Obesity-Microalbuminuria-Diabetes Mellitus, Type 2-Dyslipidemia
March 2007
Phase 3
NCT00412698
Sanofi
Obesity-Dyslipidemias
December 2006
Phase 3
NCT00459173
Sanofi
Maintenance of Smoking Cessation
November 2002
Phase 3
NCT00075205
National Institute on Alcohol Abuse and Alcoholism (NIAAA)-Sanofi-Synthelabo-National Institutes of Health Clinical Center (CC)
Healthy-Alcohol Drinking
December 31, 2003
Phase 2
NCT00481975
Sanofi
Obesity-Eating Disorders
August 2004
Phase 3
NCT00678483
Sanofi
Obesity-Weight Loss
April 2008
Phase 3
NCT00459004
Sanofi
Obesity
October 2004
Phase 2
NCT00458718
Sanofi
Smoking Cessation
September 2004
Phase 3
NCT00750347
University Hospital, Clermont-Ferrand
Pain
September 2008
Phase 1
NCT00239967
Sanofi
Dyslipidemia-Obesity
May 2005
Phase 3
NCT00481923
Sanofi
Obesity
May 2004
Phase 3
NCT00386061
Sanofi
Obesity
October 2001
Phase 3
NCT00124332
Sanofi
Coronary Atherosclerosis
January 2005
Phase 3
NCT00408148
Sanofi
Obesity
October 2006
Phase 3
NCT00257257
Sanofi
Type 2 Diabetes Mellitus
March 2005
Phase 3
NCT00434096
Sanofi
Obesity
February 2007
Phase 3
NCT00288236
Sanofi
Type 2 Diabetes Mellitus
January 2006
Phase 3
NCT00325546
Sanofi
Obesity
April 2006
Phase 3
NCT01041170
National Institute on Drug Abuse (NIDA)-National Institutes of Health Clinical Center (CC)
Cannabis-Dependence
April 16, 2006
Phase 1
NCT00656487
The Scripps Research Institute-National Institute on Drug Abuse (NIDA)
Cannabis Dependence-Cannabis Withdrawal
April 30, 2008
Phase 2
NCT00029861
Sanofi
Obesity-Weight Loss
August 2001
Phase 3
NCT00029848
Sanofi
Obesity-Diabetes Mellitus, Non-Insulin-Dependent-Obesity in Diabetes
October 2001
Phase 3
NCT00029835
Sanofi
Obesity-Dyslipidemia
September 2001
Phase 3
NCT00734123
Hospital Arnau de Vilanova-Pfizer
Atherosclerosis-Cardiovascular Diseases
April 2008
Phase 4
NCT00636766
Aristotle University Of Thessaloniki
Carotid Atherosclerosis-Stroke-Type 2 Diabetes-Metabolic Syndrome
September 2005
View MoreCollapse
References
[1].Heppenstall C, Bunce S, Smith JC. Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant. Nutr J. 2012 Jul 23;11(1):50.
[2].Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies. Neuropharmacology. 2012 Oct;63(5):9
[3].Mandhane S, Nayak P, Soni D, Jain S, Ashton JC, Rajamannar T. Induction of glucose intolerance by acute administration of rimonabant. Pharmacology. 2012;89(5-6):339-47.
[4].Leite, C.E., Mocelin, C.A., Petersen, G.O., et al. Rimonabant: An antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol Rep 61 217-224 (2009).
[5].Erdozain, A. M. et al. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: Evidence from postmortem human brain Biochemical Pharmacology (2012), 83(2), 260-268.